Trial Profile
A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Advanced breast cancer; Brain metastases; Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
- 22 Aug 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.
- 09 Jul 2018 Status changed from recruiting to active, no longer recruiting.